Home
http://www.virbac.fr/ http://www.boehringer-ingelheim.com/ http://www.novartis.com/ http://www.animalhealth.bayerhealthcare.com/
vetcontact
Vetrinär
Tiermedizin
  WELCOME  
vetcontact
Vetrinär
Tiermedizin
  Home  
  Login / Newsletter  
vetcontact
Vetrinär
Tiermedizin
  CONTACTS  
vetcontact
Vetrinär
Tiermedizin
  Classifieds  
  New Products  
  VetCompanies  
  VetSchools  
vetcontact
Vetrinär
Tiermedizin
  PROFESSION  
vetcontact
Vetrinär
Tiermedizin
  Edutainment  
  VetAgenda  
  Presentations  
  Posters  
  ESAVS  
  Specialisation  
vetcontact
Vetrinär
Tiermedizin
  INSIGHT  
vetcontact
Vetrinär
Tiermedizin
  Congress News  
  Picture Galleries  
vetcontact
Vetrinär
Tiermedizin
  PRODUCTS  
vetcontact
Vetrinär
Tiermedizin
  Bayer  
  Boehringer Ing.  
  Novartis  
  Virbac

 
  Simply book for less...  
    

Bovine    Equine    Small Animal Practice    Swine Practice    Articles    Vetjournal    
deutsch english espańol polski francais
Home / WELCOME / Archiv / Small Animal Practice /     
 
Promising novel drug for canine lymphoma
Lymphomas belong to the most common malignant multicentric neoplasias. A variety of chemotherapeutic protocols is currently recommended. In this study, 9-aminocamptothecin was used as a 72-h infusion with promising results.

A colloidal dispersion formulation of 9-aminocamptothecin (9-AC) was administered intravenously to 10 dogs with previously untreated, spontaneously occurring, multicentric lymphoma. The dogs received a 72-h infusion of 9-AC at a rate of 46.5-51.25 Āµg m2 h1 (total dose range 3.35-3.69 mg m2). This dose range was associated with myelosuppression, consisting principally of neutropenia with a nadir at 7 days following the start of infusion.

Neutropenia and thrombocytopenia were the most common toxicoses and are most likely to be dose-limiting toxicities; low-grade gastrointestinal signs were rarely seen. Concentrations of 9-AC lactone, as well as clinical toxicities, compare favourably with those found in humans.

Tumour responses were seen in all treated dogs. Response to other chemotherapy, following cessation of 9-AC treatment, was not obviously compromised even in dogs clinically resistant to 9-AC. 9-AC is a novel treatment drug for canine lymphoma, which appears to show great promise.

Source: Moore, A. S., Imondi, A. R., de Souza, P. L. & Wood, C. A. (2003): Intravenous administration of 9-aminocamptothecin to dogs with lymphoma. In: Veterinary and Comparative Oncology 1 (2), 86-93.




Tell a friend   |   Print version   |   Send this article

SMALL ANIMAL PRACTICE

Brachycephalic airway syndrome - differences between pugs and French bulldogs
Does the brachycephalic airway syndrome mean the same in all brachycephalic breeds or are there breed-specific differences? A fascinating question was raised. This retrospective study including 72 dogs aimed to compare clinical features of brachycephalic airway syndrome and long-term surgical outcomes between pugs and French bulldogs and evaluate the influence of laryngeal collapse.

  • Prognostic factors in cats with HCMmembers
  • Ureteral Papilla Implantation in Cats Undergoing Renal Transplantationmembers
  • Storage lesion in canine packed erythrocytesmembers
  • Drug-induced infiltrative lung disease with cytarabine and prednisonemembers
  • Laparoscopic-assisted Gastropexy and the Gastrointestinal Transit Time in Dogsmembers
  • Transpalpebral ultrasonographic evaluation and measurement of the optic nerve members
  • Squamous cell carcinoma mimicking orbital myofibroblastic sarcomamembers
  • Unusual case of feline acute corneal hydropsmembers
  • Shock index in identifying acute blood loss in healthy dogsmembers
  • Correlation of direct in-house cerebrospinal fluid cytology with commercial pathology results members
  • 3 Serological Tests for Early Detection Of Leptospira-specific Antibodies members
  • Patient-specific facemask to facilitate brain biopsymembers


  • [ Home ] [ About ] [ Contact / Request ][ Disclaimer ]

    Copyright © 2001-2016 VetContact GmbH
    All rights reserved